TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02889809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short Acting Beta 2 Agonist
Description: Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Short Acting Beta 2 Agonist
Description: Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
Study: NCT04107688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will use plain water as an oral rinse twice a day for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will use plain water as an oral rinse twice a day for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPE
Description: Subjects will use a cranberry-derived oral rinse twice a day for 11 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPE
Description: Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
Study: NCT01066897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Patients will received increasing dose of pramipexole
Study: NCT03997409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
Study: NCT03366233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental fatigue
Description: A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
Study: NCT04463888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: occupational therapy
Description: occupational therapy targeted to goals that are relevant to the functional needs of the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy
Description: occupational therapy targeted to goals that are relevant to the functional needs of the patient
Study: NCT03875794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation
Description: Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
Study: NCT01763645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
Study: NCT03534778

Intervention type: DIAGNOSTIC_TEST
Intervention: Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)
Description: LNY and LNR will be examined after neck dissection
Study: NCT00599599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
Study: NCT03754686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Best medical care and oral paracetamol twice daily for five days
Study: NCT01132222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study: NCT01062854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft earplugs are worn during sleep study
Description: Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups.
Study: NCT01746199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole daily prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphadoxine-pyrimethamine
Description: Intermittent preventive sulphadoxine-pyrimethamine treatment
Study: NCT02797795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEV801
Description: Dose Escalation
Study: NCT01996254

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study: NCT00602836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)
Study: NCT01810406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSE with 10 ml EVE
Description: Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSE without EVE
Description: Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
Study: NCT00602836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Study: NCT02760004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRogram In Support of Moms (PRISM)
Description: * Access to MCPAP for Moms~* PRogram In Support of Moms Toolkit with Stepped Care Algorithms~* Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~* Customization of depression screening for each practice~* Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~* Employ psychoeducation and Motivational Interviewing to engage patients with depression~* medical assistant champion and psychiatrist contact bi-weekly to review cases~* Stepped care treatment to depression screening/assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCPAP for Moms
Description: * 30-60 minute presentation on perinatal depression~* Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~* Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~* Access to assessment and treatment protocols in Provider Toolkit~* Resource provision/referrals
Study: NCT02260765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS
Description: The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
Study: NCT03486873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 or 400 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 or 400 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 or 400 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 or 400 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: IV infusion or oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: IV infusion or oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: IV infusion or oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsules
Study: NCT03484702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCAR017
Description: Specified dose on specified days
Study: NCT01536756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention -- Physical Rehabilitation Program
Description: The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Control Group
Description: The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
Study: NCT03462329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics (preferentially oral doxycycline 100 mg bid)
Description: Patients will be treated with antibiotics for Lyme disease.
Study: NCT04253925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kegel exercises
Description: global postural correction exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel exercises
Description: global postural correction exercises
Study: NCT00144521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4week(i.v.)for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRA placebo
Description: 0mg/kg/4week(i.v.) for 24 weeks
Study: NCT01618305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants received one 600 mg tablet of efavirenz each night from entry through delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
Study: NCT03103581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: BLI4700 Bowel Preparation (Investigational Regimen)
Study: NCT01205698

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional drink
Study: NCT01962883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye.
Study: NCT00891683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEG33773 oral dosing
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEG33773 oral dosing
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEG33773 oral dosing
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AEG33773 oral dosing
Description: AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
Study: NCT03599310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning
Description: The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
Study: NCT01956357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land Exercise
Study: NCT00400010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert System Intervention
Description: Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
Study: NCT00440050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA (Docosahexaenoic Acid)
Description: 950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules twice a day for 18 months
Study: NCT03421054

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: patients assuming nutraceutical containing HA
Description: pain reduction of the affected knee in the patients assuming nutraceutical containing HA
Study: NCT02911389

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home PT via web-based platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home PT via paper manual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: outpatient PT
Study: NCT00144521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: 8mg/week(p.o.) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX placebo
Description: 0mg/week(p.o.) for 24 weeks
Study: NCT01902745

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Theory
Description: Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
Study: NCT02236962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine, pioglitazone
Study: NCT00953654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: 6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance Training
Description: Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
Study: NCT01566266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 2 capsules of 250mg, 3 times per day during 1 week
Study: NCT02232113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERA
Description: changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
Study: NCT03753438

Intervention type: PROCEDURE
Intervention: Intragstric Ballooning
Description: Intragstric Ballooning will be put.